Travere Therapeutics, Inc. (NASDAQ: TVTX ) specializes in treatments for rare kidney and metabolic diseases. TVTX's portfolio includes FDA-approved drugs like Filspari [Sparsentan] for IgA Nephropathy [IgAN] and Thiola [Tiopronin] for cystinuria. Filspari received full FDA approval in September 2024, expanding its label and expanding patient access. However, its Phase My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Naciona ...